Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | CTSS | P25774 | 6/20 | 0.42 |
| ▸ | CTSB | P07858 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398714 | 0.86 | CTSB (0.39) | CTSSCTSBCTSLMAPTPOLB | |
| SCHEMBL14427090 | 0.82 | CTSS (0.41) | SMN1; SMN2NPC1RAB9ACTSSCTSB | |
| SCHEMBL5385250 | 0.79 | — | — | |
| SCHEMBL5394349 | 0.78 | — | — | |
| SCHEMBL5384543 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9ACTSSCTSB | |
| SCHEMBL5394166 | 0.76 | TDP1 (0.38) | LMNAMAPTTP53POLB | |
| SCHEMBL14427071 | 0.75 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ALMNAKMT2A | |
| SCHEMBL5384676 | 0.74 | ALDH1A1 (0.39) | SMN1; SMN2RAB9ACTSSPOLB | |
| SCHEMBL5392286 | 0.72 | CTSB (0.41) | CTSSCTSBLMNA | |
| SCHEMBL5427338 | 0.71 | PRSS1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | claimed |
| US-7226921-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | claimed |
| US-6977256-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | claimed |
| EP-1446392-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-08-18 | — | — | EP | claimed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003042197-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-22 | — | — | WO | claimed |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-7226921-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-6977256-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| EP-1446392-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003042197-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | SMN1; SMN2 2868/4885NPC1 40/4885RAB9A 494/4885 |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSE | SMN1; SMN2 2868/4885NPC1 40/4885RAB9A 494/4885 |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | SMN1; SMN2 2629/4885NPC1 36/4885RAB9A 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.